Healthcare
Live Price
Offline$80.79
+0.02% today
1Y Change
+390.67%
Window
Jun 20, 2025 → Jun 5, 2026
Coverage: 241 bars · Jun 20, 2025 → Jun 5, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Spyre Therapeutics, Inc. (SYRE) is a Healthcare stock with a market cap of $4.19B and listed on NASDAQ. The stock last traded around $80.79 and up 390.7% across the available one-year price window (Jun 20, 2025 → Jun 5, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +37.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +37.7%, free cash flow -7.5% with operating margin -231.6% and ROIC -29.1%. Valuation already assumes a fairly strong business story at price/sales 46.3. Stock Foundry combines SYRE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SYRE
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SYRE Max Drawdown
-16.79%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SYRE and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$18.7M
+704.6% YoY
FY Net Income
-$65.8M
+21.5% YoY
Free Cash Flow
-$54.3M
+32.3% YoY
Revenue Growth
+0.0%
EPS Growth
+37.7%
Gross Margin
0.0%
Net Margin
-171.5%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 886K | 2M | 19M |
| Gross Profit | -172M | 0 | 886K | 2M | 19M |
| Operating Income | -210M | -209M | -242M | -85M | -66M |
| EBITDA | -210M | -208M | -128M | -83M | -64M |
| Net Income | -155M | -208M | -339M | -84M | -66M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 86M | 89M | 189M | 35M | 15M |
| Total Assets | 778M | 608M | 342M | 71M | 110M |
| Total Liabilities | 63M | 91M | 158M | 21M | 26M |
| Shareholder Equity | 715M | 518M | 184M | 50M | 84M |
| Total Debt | 0 | 0 | 0 | 5M | 5M |
| Net Debt | -86M | -89M | -189M | -30M | -10M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
54M
+33.0% YoY
Capital Expenditures
573K
-1407.9% YoY
Free Cash Flow
54M
+32.3% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
-231.6%
Net Margin
-171.5%
ROE
-29.4%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.